Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Fig. 2

Enhancement of KLH-specific immune response by anti-CTLA-4 is attenuated by continuous combination treatment with selumetinib. a Schema showing s.c. injection of keyhole limpet hemocyanin (KLH) in Complete Freund’s Adjuvant (CFA) on day 0.Treatment groups were dosed with either saline/vehicle controls, anti-CTLA-4, or combination of anti-CTLA-4 and selumetinib. Two concurrent dosing regimens were tested for selumetinib and anti-CTLA-4 combination. On day 7, splenocytes were restimulated ex vivo with KLH antigen or ovalbumin (OVA), irrelevant antigen control, for 72 h. b KLH-specific IFNγ production by splenocyte cultures are shown (calculated as the IFNγ response to KLH (pg/mL) minus the IFNγ response to OVA (pg/mL)). Data shown are means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001 as determined by unpaired t-test between indicated groups

Back to article page